Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines.
作者信息
Wang Jiale, Qiu Tianyu, Ren Shengxiang
机构信息
School of Medicine, Tongji University, Shanghai 200331, China.
Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
出版信息
Cancer Biol Med. 2025 Feb 24;22(2):77-82. doi: 10.20892/j.issn.2095-3941.2024.0497.
Abstract
摘要
相似文献
1
Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines.
Cancer Biol Med. 2025 Feb 24;22(2):77-82. doi: 10.20892/j.issn.2095-3941.2024.0497.
2
Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022.
Transl Breast Cancer Res. 2022 Apr 30;3:13. doi: 10.21037/tbcr-22-21. eCollection 2022.
3
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.
4
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.
Cancer Commun (Lond). 2024 Jan;44(1):127-172. doi: 10.1002/cac2.12516. Epub 2023 Dec 31.
5
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update.
Cancer Commun (Lond). 2025 Mar;45(3):332-379. doi: 10.1002/cac2.12639. Epub 2024 Dec 31.
6
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC.
Cancer Biol Med. 2025 Feb 24;22(3):191-6. doi: 10.20892/j.issn.2095-3941.2024.0592.
7
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554.
8
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018.
Chin J Cancer Res. 2019 Jun;31(3):423-425. doi: 10.21147/j.issn.1000-9604.2019.03.03.
9
CSCO guidelines for colorectal cancer version 2022: Updates and discussions.
Chin J Cancer Res. 2022 Apr 30;34(2):67-70. doi: 10.21147/j.issn.1000-9604.2022.02.01.
10
CSCO guidelines for colorectal cancer version 2024: Updates and discussions.
Chin J Cancer Res. 2024 Jun 30;36(3):233-239. doi: 10.21147/j.issn.1000-9604.2024.03.01.
本文引用的文献
1
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
Lancet Respir Med. 2024 Dec;12(12):958-966. doi: 10.1016/S2213-2600(24)00211-X. Epub 2024 Sep 10.
2
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
J Clin Oncol. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9.
3
Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.
J Clin Oncol. 2024 Nov;42(31):3680-3691. doi: 10.1200/JCO.23.02363. Epub 2024 Jul 26.
4
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).
J Thorac Oncol. 2024 Jun;19(6):912-927. doi: 10.1016/j.jtho.2024.01.013. Epub 2024 Jan 25.
5
Repotrectinib in Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299.
6
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
Lancet Respir Med. 2024 Mar;12(3):217-224. doi: 10.1016/S2213-2600(23)00379-X. Epub 2023 Dec 12.
7
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
8
Trastuzumab Deruxtecan in Patients With -Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial.
J Clin Oncol. 2023 Nov 1;41(31):4852-4863. doi: 10.1200/JCO.23.01361. Epub 2023 Sep 11.
9
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial.
Signal Transduct Target Ther. 2023 Aug 14;8(1):301. doi: 10.1038/s41392-023-01538-w.
10
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial.
Signal Transduct Target Ther. 2023 Jun 30;8(1):249. doi: 10.1038/s41392-023-01454-z.
Zotero 插件